Why would a patient be prescribed both Adderall XR (mixed amphetamine salts) 20 mg and Vyvanse (lisdexamfetamine) 30 mg simultaneously?

Why Would a Patient Be on Both Adderall XR 20mg and Vyvanse 30mg Simultaneously?

The most likely reason is "dose sculpting" to extend symptom coverage throughout the day, though this practice has limited evidence and should generally be avoided. Both medications are amphetamine-based stimulants (Adderall XR contains mixed amphetamine salts, Vyvanse is lisdexamfetamine which converts to d-amphetamine), and combining them represents using two medications from the same class simultaneously.

Evidence-Based Rationale

According to AACAP guidelines, two stimulant formulations (short and long-acting) may be used to "sculpt" dosing for coverage of extended periods of time 1. However, this guidance specifically refers to combining immediate-release with extended-release formulations of the same stimulant (e.g., Adderall IR with Adderall XR, or methylphenidate IR with Concerta), not combining two different long-acting amphetamine products.

Critical Limitation

The guidelines explicitly state there is "limited support" for combining medications from the same class as an initial treatment approach or specific endpoint 1. The exception noted is during medication transitions when patients temporarily take two medications while switching from one to another 1.

Possible Clinical Scenarios

1. Extended Duration Coverage (Most Likely)

• Adderall XR duration: approximately 10-12 hours
• Vyvanse duration: up to 14 hours 2
• A prescriber might add one to the other attempting to cover an exceptionally long day (e.g., early morning through late evening)
• However, this approach lacks evidence and increases risk of adverse effects

2. Medication Transition Period

• Patient may be switching from one to the other
• Both prescribed temporarily during crossover
• Should be short-term only 1

3. Inadequate Response Management (Questionable Practice)

• Provider attempting to increase total amphetamine dose by combining products
• This is problematic: Simply increasing the dose of a single agent would be more appropriate
• Maximum recommended daily doses: 60mg for mixed amphetamine salts 3

4. Comorbidity Treatment (Unlikely)

Guidelines support combining stimulants with different medication classes for comorbid conditions (e.g., stimulant + SSRI for ADHD + anxiety) 1, but not two stimulants together.

Safety Concerns

This combination raises significant red flags:

• Cardiovascular risk: Additive effects on blood pressure and heart rate 4
• Growth suppression: Cumulative effect in children/adolescents 4
• Appetite suppression and weight loss: Both medications cause these effects 4
• Insomnia: Overlapping long-acting formulations may severely disrupt sleep
• Abuse potential: Having two controlled substances increases diversion risk 5
• Psychiatric symptoms: Increased risk of psychotic symptoms, mania, aggression 4

What Should Be Done Instead

If a single long-acting stimulant provides inadequate coverage:

1. Optimize the single agent first: Increase dose of one medication to maximum recommended levels before adding another
2. Add short-acting stimulant for specific times: Use immediate-release amphetamine or methylphenidate for afternoon/evening "booster" doses 3
3. Switch to longer-acting option: Try Vyvanse alone (up to 70mg) given its 14-hour duration 2
4. Consider non-stimulant augmentation: Add atomoxetine, guanfacine, or clonidine if stimulant alone insufficient 6, 5
5. Reassess diagnosis and psychosocial factors: Ensure symptoms aren't better addressed through behavioral interventions 1

Clinical Pitfalls

• Mistaking tolerance for inadequate coverage: Patients may need medication holidays or dose optimization rather than adding medications
• Treating psychosocial stressors with medication: Irritability from life challenges shouldn't automatically trigger medication additions 1
• Pressure from stakeholders: Parents/teachers requesting medication adjustments for normal behavioral fluctuations 1

Bottom Line

This combination lacks evidence-based support and should prompt medication review. The prescriber needs a clear, documented rationale 1. If truly necessary for extended coverage, a more appropriate approach would be a single long-acting stimulant plus an immediate-release booster, not two long-acting amphetamine products simultaneously. Consider consulting with an ADHD specialist if symptom control remains inadequate with standard approaches.